Drug Profile
Metformin/rosuvastatin - Hanmi Pharmaceutical
Alternative Names: HCP-1201; Rosuvastatin/metforminLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Class Antihyperglycaemics; Antihyperlipidaemics; Biguanides; Cardiovascular therapies; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hyperlipidaemia; Type 2 diabetes mellitus
Most Recent Events
- 31 Jan 2014 Hanmi Pharmaceutical completes a phase I trial in Healthy volunteers in South Korea (NCT02026817)
- 01 Jan 2014 Hanmi Pharmaceutical completes enrolment in a phase I trial in Healthy volunteers in South Korea (NCT02026817)
- 31 Dec 2013 Hanmi Pharmaceutical completes a phase I trial in Healthy volunteers in South Korea (NCT02011633)